Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemotherapyResults from the Phase 1b/2 EPCORE® NHL-2 trial show fixed-duration epcoritamab plus standard of care R-mini-CHOP demonstrated sustained minimal residual disease (MRD) negativity and durable remissions in